ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jos G. Maessen
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fransen, E. J.
Right arrow Articles by Glatz, J. F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fransen, E. J.
Right arrow Articles by Glatz, J. F. C.

Ann Thorac Surg 1998;65:48-53
© 1998 The Society of Thoracic Surgeons

Original Articles: Cardiovascular

Demonstration of Ischemia-Reperfusion Injury Separate From Postoperative Infarction in Coronary Artery Bypass Graft Patients

Erik J. Fransen, MSc, Jos G. Maessen, MD, PhD, Wim T. Hermens, PhD, Jan F. C. Glatz, PhD

Department of Cardiopulmonary Surgery, Academic Hospital Maastricht, Maastricht, the Netherlands,
Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands

Accepted for publication June 25, 1997.

Dr Maessen, Department of Cardiopulmonary Surgery, Academic Hospital Maastricht, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands (e-mail: jma@scpc.azm.nl).

Background. In patients undergoing coronary artery bypass grafting there are two possible causes of myocardial injury: (1) global ischemic myocardial injury during aortic cross-clamping and subsequent reperfusion, and (2) postoperative myocardial infarction. We studied the use of cardiac marker proteins to specifically and separately detect such injury.

Methods. Serum levels of enzymes (creatine kinase and creatine kinase-MB) and nonenzymatic proteins (fatty acid-binding protein and myoglobin) were measured in 8 low-risk patients undergoing coronary artery bypass grafting with cardiopulmonary bypass, 8 low-risk patients undergoing coronary artery bypass grafting without cardiopulmonary bypass, and 39 high-risk patients undergoing coronary artery bypass grafting with cardiopulmonary bypass, of whom 7 experienced a postoperative myocardial infarction.

Results. At 0.5 hours after reperfusion significantly increased plasma levels of all markers were noted in patients having the operation with cardiopulmonary bypass, but not in patients having the operation without cardiopulmonary bypass. In patients who had a postoperative myocardial infarction, a second significant increase of each marker was found, but that of fatty acid-binding protein was recorded 4 hours earlier than that of creatine kinase, creatine kinase-MB, or myoglobin.

Conclusions. Perioperative myocardial injury can be diagnosed from the release of cardiac marker proteins into plasma already at 0.5 hours after the start of reperfusion. For early assessment of postoperative myocardial infarction, fatty acid-binding protein is a more suitable plasma marker than are creatine kinase, creatine kinase-MB, or myoglobin.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
L. Petaja, M. Salmenpera, K. Pulkki, and V. Pettila
Biochemical Injury Markers and Mortality After Coronary Artery Bypass Grafting: A Systematic Review.
Ann. Thorac. Surg., June 1, 2009; 87(6): 1981 - 1992.e3.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. Hasegawa, N. Yoshimura, S. Oka, Y. Ootaki, Y. Toyoda, and M. Yamaguchi
Evaluation of heart fatty acid-binding protein as a rapid indicator for assessment of myocardial damage in pediatric cardiac surgery
J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1697 - 1702.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. K. Shernan, J. C. K. Fitch, N. A. Nussmeier, J. C. Chen, S. A. Rollins, C. F. Mojcik, K. J. Malloy, T. G. Todaro, T. Filloon, S. W. Boyce, et al.
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass
Ann. Thorac. Surg., March 1, 2004; 77(3): 942 - 949.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. J. Fransen, J. H. C. Diris, J. G. Maessen, W. Th. Hermens, and M. P. van Dieijen-Visser
Evaluation of "New" Cardiac Markers for Ruling Out Myocardial Infarction After Coronary Artery Bypass Grafting
Chest, October 1, 2002; 122(4): 1316 - 1321.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T. Petzold, P. Feindt, U. Sunderdiek, U. Boeken, Y. Fischer, and E. Gams
Heart-type fatty acid binding protein (hFABP) in the diagnosis of myocardial damage in coronary artery bypass grafting
Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 859 - 864.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
E. J Fransen, J. G Maessen, Wim.T. Hermens, J. F.C Glatz, and W. A Buurman
Peri-operative myocardial tissue injury and the release of inflammatory mediators in coronary artery bypass graft patients
Cardiovasc Res, March 1, 2000; 45(4): 853 - 859.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. C. K. Fitch, S. Rollins, L. Matis, B. Alford, S. Aranki, C. D. Collard, M. Dewar, J. Elefteriades, R. Hines, G. Kopf, et al.
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Circulation, December 21, 1999; 100(25): 2499 - 2506.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1998 by The Society of Thoracic Surgeons.